-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Chimeric antigen receptor (CAR)-T cell therapy has shown significant clinical effects on B-cell malignant tumors, but there are defects in antigen escape and tumor recurrence.
CAR-T
Heterogeneous multiple myeloma (MM) that is resistant to B cell maturation antigen (BCMA) traditional CAR-T cell therapy has strong activity, and the results of the study have been published in Nat Commun.
The results showed that, compared with T cells expressing a single BCMA and CS1 CARs simultaneously, BCMA/CS1 bispecific CAR-T cells showed excellent CAR expression and function.
In summary, BCMA/CS1 bispecific CAR is a promising treatment method to prevent antigen escape when CAR-T cells treat MM.
Original source:
Eugenia Zah, et al.
ncbi.
nlm.
nih.
gov/32385241/" target="_blank" rel="noopener">Systematically optimized BCMA / CS1 bispecific CAR- T cells robustly control heterogeneous multiple myeloma
in this message